trending Market Intelligence /marketintelligence/en/news-insights/trending/Yakhd5Z9Km8cNL92LIGXEw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Diaceutics plans IPO on London Stock Exchange's AIM market

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Diaceutics plans IPO on London Stock Exchange's AIM market

Belfast, U.K.-based healthcare technology company Diaceutics PLC is planning an IPO on the AIM market of the London Stock Exchange.

The Northern Irish company, which provides data analytics and implementation services, intends to apply for admission of its issued and to be issued ordinary shares to trading on the exchange and is expected to have a market capitalization on admission of about £53 million.

Diaceutics has also conditionally raised £17 million by selling 22,368,427 of its new ordinary shares at 76 pence apiece. In addition, 4,934,205 existing ordinary shares have been placed on behalf of existing shareholders.

Cenkos Securities PLC acted as the nominated adviser and broker for Diaceutics in the private placement.

Diaceutics expects the private placement to generate about £15.2 million in net proceeds, of which £5.5 million will be used to acquire additional data sets to enhance the company's current coverage as well as add new disease data and implement a partnership to develop artificial intelligence analysis.

Moreover, £3 million of the net proceeds will be used to develop Diaceutics' software as a service platform NEXUS — a software distribution model in which the company hosts applications and makes them available to customers over the internet.

About £3 million of the net proceeds will pay the Diaceutics' existing debt facilities and an outstanding director loan and £1.2 million will be used to strengthen the company's balance sheet. Net proceeds of about £2.5 million will be used for working capital as well as the development of international markets either organically or through acquisition.

Diaceutics expects its shares will begin trading on the AIM market under the symbol DXRX on or about March 21.

Peter Keeling is the CEO of Diaceutics, according to data from S&P Global Market Intelligence.

Diaceutics is backed by Silicon Valley Bank and private equity firm WhiteRock Capital Partners LLP.